Covigenix VAX 002
Alternative Names: Covigenix VAX-002; DNA SARS-CoV-2 vaccine - Entos Pharmaceuticals/Epivax; ENTVAX-002; SARS-CoV-2 DNA Vaccine - Entos Pharmaceuticals/EpivaxLatest Information Update: 28 May 2025
At a glance
- Originator Entos Pharmaceuticals; EpiVax
- Class COVID-19 vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Canada (Parenteral)
- 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 16 Apr 2021 Preclinical trials in COVID-2019 infections (Prevention) in Canada (Parenteral)